指南与共识血栓与止血

新生儿中心静脉导管观察性血栓研究(NEOCLOT):国家指南管理新生儿导管相关静脉血栓的评估

NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): evaluation of a national guideline on management of neonatal catheter-related venous thrombosis.
指南 / 共识 · J Thromb Haemost · 2022-12-22

这项前瞻性多中心观察性研究纳入2014至2019年荷兰≤6月龄的115例导管相关静脉血栓新生儿,评估国家指南管理的有效性与安全性。复发性静脉血栓事件2例(1.7%),因CVTE死亡1例(0.9%),大出血9例(7.8%)。结论认为按荷兰指南管理可降低复发性静脉血栓事件及血栓相关死亡,但大出血仍需关注,指南调整或可改善安全性。

要点

  • 115例新生儿中复发性静脉血栓2例(1.7%),因CVTE死亡1例(0.9%)。
  • 大出血9例(7.8%):重组组织型纤溶酶原激活剂7例中2例(29%),低分子肝素63例中7例(11%)。
  • 低分子肝素相关7例出血中5例为皮下导管给药并发症。

核心结论

  • 按荷兰CVTE管理指南管理新生儿CVTE,复发性静脉血栓事件及血栓相关死亡发生率低。
  • 大出血发生于7.8%的患儿,特定指南调整或可改善疗效、尤其安全性。

研究设计与样本

  • 前瞻性、多中心、观察性研究,纳入2014至2019年荷兰≤6月龄的CVTE婴儿。
  • CVTE分为静脉血栓与右心房血栓,各自采用相应治疗算法。
  • 主要结局为复发性静脉血栓事件和/或因CVTE死亡,以及大出血。

主要发现

  • 共纳入115例新生儿,62%为男性,79%为早产儿。
  • CVTE估计发病率为每1000例新生儿重症监护病房入住4.0例。
  • 复发性血栓发生2例(1.7%),因CVTE死亡1例(0.9%)。
  • 大出血9例(7.8%):重组组织型纤溶酶原激活剂治疗7例中2例(29%),低分子肝素治疗63例中7例(11%)。
  • 低分子肝素相关7例出血中5例为皮下导管给药的并发症。

关键数值与推荐

  • CVTE分为静脉血栓与右心房血栓,分别采用各自治疗算法。
  • 高危右心房血栓给予重组组织型纤溶酶原激活剂。
  • 低分子肝素经皮下导管给药。

临床怎么用

  • 作者认为按荷兰CVTE管理指南管理新生儿CVTE可降低复发性静脉血栓事件及血栓相关死亡。
  • 作者建议对指南进行特定调整,以改善疗效、尤其安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In critically ill (preterm) neonates, catheter-related venous thromboembolism (CVTE) can be a life-threatening complication. Evidence on optimal management in the literature is lacking. In the Netherlands, a consensus-based national management guideline was developed to create uniform CVTE management. OBJECTIVES: To evaluate the efficacy and safety of the national guideline. METHODS: This prospective, multicenter, observational study included all infants aged ≤6 months with CVTE in the Netherlands between 2014 and 2019. CVTE was divided into thrombosis in veins and that in the right atrium, with their own treatment algorithms. The primary outcomes were recurrent venous thrombotic events (VTEs) and/or death due to CVTE as well as major bleeding. RESULTS: Overall, 115 neonates were included (62% male; 79% preterm). The estimated incidence of CVTE was 4.0 per 1000 neonatal intensive care unit admissions. Recurrent thrombosis occurred in 2 (1.7%) infants and death due to CVTE in 1 (0.9%) infant. Major bleeding developed in 9 (7.8%) infants: 2 of 7 (29%) on recombinant tissue plasminogen activator, which was given for high-risk right-atrium thrombosis, and 7 of 63 (11%) on low-molecular-weight heparin (LMWH). Five of the 7 bleedings because of LMWH were complications of subcutaneous catheter use for LMWH administration. CONCLUSION: The management of neonatal CVTE according to the Dutch CVTE management guideline led to a low incidence of recurrent VTEs and death due to VTEs. Major bleeding occurred in 7.8% of the infants. Specific guideline adjustments may improve efficacy and, especially, safety of CVTE management in neonates.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. van Ommen CH, Bergman KA, Boerma M, et al. NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): evaluation of a national guideline on management of neonatal catheter-related venous thrombosis. J Thromb Haemost. 2022. PMID: 36696213. doi:10.1016/j.jtha.2022.11.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。